Key Details
Price
$82.62Last Dividend
$0.52Annual ROE
87.29%Beta
0.77Events Calendar
Next earnings date:
Feb 05, 2025Recent quarterly earnings:
Nov 06, 2024Recent annual earnings:
Feb 02, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
Aug 16, 2024Next split:
N/ARecent split:
Sept 20, 2023Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Novo Nordisk reported on Wednesday that its emissions increased by 23% in 2024 and are expected to continue rising until the end of the decade due to the increased production of its popular obesity medication, Wegovy.
Novo Nordisk reports a higher-than-expected net profit, driven by a 107% increase in Wegovy sales during the fourth quarter.
Novo Nordisk, a company that makes drugs for weight loss and diabetes, reported higher-than-expected operating profits for the fourth quarter on Wednesday. However, it also predicted that sales growth will be slower in 2025 compared to last year.
Bagsværd, 5 February 2025 - Financial report covering the time from 1 January 2024 to 31 December 2024.
SAN DIEGO, Feb. 4, 2025 /PRNewswire/ -- Robbins LLP is notifying shareholders that a class action lawsuit has been initiated for all investors who bought or acquired Novo Nordisk A/S (NYSE: NVO) securities from November 2, 2022, to December 19, 2024. Novo is a healthcare firm that specializes in the research, development, production, and global distribution of pharmaceutical products.
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you experienced a loss from your investment in Novo Nordisk A/S (NYSE:NVO) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=127175&wire=1 or reach out to Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you experienced a loss from your investment in Novo Nordisk A/S (NYSE:NVO) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=127139&wire=1 or reach out to Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you experienced a loss from your investment in Novo Nordisk A/S (NYSE:NVO) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=127112&wire=1 or reach out to Joseph E. Levi, Esq.
On February 4, 2025, Bleichmar Fonti & Auld LLP, a prominent securities law firm, announced that they have filed a lawsuit against Novo Nordisk (NYSE:NVO) and some of its top executives for possible breaches of federal securities laws. If you have invested in Novo Nordisk, you are invited to find out more by visiting https://www.bfalaw.com/cases-investigations/novo-nordisk-as.
On February 4, 2025, Pomerantz LLP announced that a class action lawsuit has been initiated against Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO). Investors who are affected are encouraged to reach out to Danielle Peyton at [email protected] or call 646-581-9980, or toll-free at 888.4-POMLAW, Ext.
FAQ
- What is the primary business of Novo Nordisk A/S?
- What is the ticker symbol for Novo Nordisk A/S?
- Does Novo Nordisk A/S pay dividends?
- What sector is Novo Nordisk A/S in?
- What industry is Novo Nordisk A/S in?
- What country is Novo Nordisk A/S based in?
- When did Novo Nordisk A/S go public?
- Is Novo Nordisk A/S in the S&P 500?
- Is Novo Nordisk A/S in the NASDAQ 100?
- Is Novo Nordisk A/S in the Dow Jones?
- When was Novo Nordisk A/S's last earnings report?
- When does Novo Nordisk A/S report earnings?